Cargando…

Carbon nanodots constructed by ginsenosides and their high inhibitory effect on neuroblastoma

BACKGROUND: Neuroblastoma is one of the common extracranial tumors in children (infants to 2 years), accounting for 8 ~ 10% of all malignant tumors. Few special drugs have been used for clinical treatment currently. RESULTS: In this work, herbal extract ginsenosides were used to synthesize fluoresce...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yingnan, Xiao, Lizhi, Wang, Jifeng, Tian, Tenghui, Liu, Guancheng, Zhao, Yu, Guo, Jiajuan, Zhang, Wei, Wang, Jiawen, Chen, Changbao, Gao, Wenyi, Yang, Bai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386222/
https://www.ncbi.nlm.nih.gov/pubmed/37507785
http://dx.doi.org/10.1186/s12951-023-02023-w
Descripción
Sumario:BACKGROUND: Neuroblastoma is one of the common extracranial tumors in children (infants to 2 years), accounting for 8 ~ 10% of all malignant tumors. Few special drugs have been used for clinical treatment currently. RESULTS: In this work, herbal extract ginsenosides were used to synthesize fluorescent ginsenosides carbon nanodots via a one-step hydrothermal method. At a low cocultured concentration (50 µg·mL(− 1)) of ginsenosides carbon nanodots, the inhibition rate and apoptosis rate of SH-SY5Y cells reached ~ 45.00% and ~ 59.66%. The in vivo experiments showed tumor volume and weight of mice in ginsenosides carbon nanodots group were ~ 49.81% and ~ 34.14% to mice in model group. Since ginsenosides were used as sole reactant, ginsenosides carbon nanodots showed low toxicity and good animal response. CONCLUSION: Low-cost ginsenosides carbon nanodots as a new type of nanomedicine with good curative effect and little toxicity show application prospects for clinical treatment of neuroblastoma. It is proposed a new design for nanomedicine based on bioactive carbon nanodots, which used natural bioactive molecules as sole source. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-02023-w.